Hi, everyone. Let's get started. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Priyanka Grover, and I'm part of the JPMorgan Biotech team. Today, our next presenting company is ...

Recursion Pharmaceuticals, Inc. (RXRX) recently received a notable upgrade from JP Morgan analyst Eric Joseph, who shifted his rating to “Overweight” on December 17, 2025. This upgrade comes as the ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

ORLANDO, Fla. – Something cool already started this May—palindrome dates! That’s right, a string of days that read the same backward and forward, creating a rare and magical moment on the calendar.

PORTLAND, Ore. (KOIN) — A 10-day stretch in May is being called the palindrome dates due to the forward and backward pattern that takes shape. The palindrome dates are from May 20, 2025 to May 29, ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

RXRX's CDK7 inhibitor REC-617 has demonstrated activity but additional data from the ELUCIDATE trial in various solid tumors isn't expected until H2'25. Near-term catalysts include phase 2 TUPELO ...

SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Executives from Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company, visit the Nasdaq MarketSite in Times Square on January 22 to ring the Nasdaq Opening Bell and celebrate the “Era of ...